Collaboration agreement between Affidea Spain and Lyx Instituto de Urología

  • Affidea Spain will have Lyx Instituto de Urología corners in its outpatient centers in Madrid and will perform all of its radiodiagnostic tests.

Madrid, November 15, 2022-. Affidea, Europe's largest provider of advanced diagnostic, outpatient and oncology services, has announced an exclusive collaboration agreement with Lyx Instituto de Urología, a national reference urology center, whereby Affidea Spain will perform all diagnostic imaging tests at Lyx Instituto de Urología, which will also have corners in Affidea's outpatient centers in the Community of Madrid.

In this way, Lyx Urology will refer to Affidea all the patients treated in its centers who need a diagnostic imaging test in magnetic resonance, PET-CT and CT techniques. Both companies agree to initiate the project with the aim that the urology specialty to be developed in Affidea's polyclinic centers will be carried out by professional staff belonging to the Lyx Urology group.

To this end, both parties will work on the unification of the urology service in Affidea polyclinics so that they become part of the Lyx Urology network. This project will begin to be developed in the Community of Madrid with the aim of extending to other centers and regions where Affidea has or may have a presence in the future.

Theo Kravvas, Country Manager of Affidea Spain, states that "we are very pleased to announce this strategic agreement with LYX Instituto de Urología. We share the same values in terms of quality and patient care, and we have been able to bring together the strengths and skills of both groups with this agreement. For our part, this partnership is very important and is fully aligned with our strategy to further develop certain subspecialties, not only in diagnostic imaging but also in the course of the disease, and to be able to offer holistic treatment to patients and a more comprehensive service to our partners. We are starting our partnership with LYX in Madrid and look forward to expanding our collaboration in other regions."

Dr. Juan Ignacio Martínez-Salamanca, Medical Director of Lyx Instituto de Urología, points out that "initiating this strategic collaboration with an entity such as Affidea means emphasizing our principle of excellence in patient care and the firm commitment to cutting-edge urology that we have always pursued. This agreement allows us to deploy our model of super-specialized urological care by a team of renowned professionals working in an interdisciplinary way, in Affidea's outpatient centers, in a way that leads to an increase in the quality of care, ensuring continuity in the processes, within the framework of a model of shared decisions. For us, being able to count on a centralized and high quality diagnostic imaging service, a key element in our specialty, represents a giant step forward. On behalf of the team of professionals at Lyx Instituto de Urología, we would like to highlight the great human and professional quality of the Affidea España team, which I am sure will guarantee the sustained success of this agreement".

Affidea Spain has 43 centers nationwide, serving more than 545,000 patients each year and working with more than 1,100 professionals. Affidea has a reinforced capacity in outpatient services that allows it to be one of the preferred healthcare providers for companies and private health insurers.

Lyx Instituto de Urología is a comprehensive urology center with a high level of technical and human super-specialization, with a team of more than 50 professionals who treat more than 40,000 patients a year. Pioneers in fusion biopsy and focal treatment of prostate cancer in Spain, Lyx Instituto de Urología specializes in robotic surgery and minimally invasive techniques for the treatment of prostate pathology, while it is a national and international reference in the field of andrology and urogenital reconstructive and prosthetic surgery.

About Affidea Spain

Affidea España ( is a leading medical provider of diagnostic imaging, nuclear medicine and outpatient medical specialties, with 43 centers nationwide. Affidea España performs more than 900,000 diagnostic imaging examinations each year, offering a medical service of excellence at the forefront of patient care. The company works with more than 1,100 professionals. Affidea Spain is recognized for its focus on patient safety, having all its centers accredited for excellence in nuclear medicine by the European Union of Medical Specialties (UEMS) and the European Board of Nuclear Medicine (EBNM).

Media contact: Elena Ayuso - 656 321 906 - -

About Affidea Group

Affidea Group ( is Europe's largest provider of advanced diagnostic imaging, outpatient and cancer treatment services. Founded in 1991, the company operates 329 medical centers in 15 countries and provides advanced diagnostic, outpatient and cancer treatment services to more than 12 million patients a year. Thanks to its high standards in patient safety, Affidea is the most awarded provider of medical imaging services in Europe. More than half of the centers awarded 5 stars in the Eurosafe Wall of Stars, accredited by the European Society of Radiology in Europe, are Affidea centers. In June this year, Affidea was awarded the Diagnostic Provider of the Year Award at the HealthInvestor Awards 2022.

About Lyx

Lyx Instituto de Urología, founded in 2014 by Dr. Juan Ignacio Martínez-Salamanca with the aim of offering a comprehensive urological service of the highest level, stands out for its innovative and avant-garde spirit, being a pioneer in Spain in the incorporation of the most advanced technology and in the performance of minimally invasive treatments. It is made up of a medical team of more than 30 renowned professionals, all of them specialists in specific areas of urology, who combine their clinical vocation with teaching and research, supported by a team of nurses, assistants and management professionals whose common vocation is to ensure the best clinical care and an excellent patient experience, in all processes, from the first contact, to discharge and subsequent follow-up.

Media contact: Belén Fernández Zuñiga -